Katja von Hoff

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5109950/publications.pdf

Version: 2024-02-01

80	9,721	101543	79698
papers	citations	36	73
		h-index	g-index

81	81	81	11160
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
2	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
3	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	16.8	933
4	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
5	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	27.8	520
6	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	7.7	478
7	Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis. Journal of Clinical Oncology, 2010, 28, 4961-4968.	1.6	273
8	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	7.7	271
9	Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial. Journal of Clinical Oncology, 2012, 30, 3187-3193.	1.6	270
10	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	10.7	268
11	Childhood cancer predisposition syndromesâ€"A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200
12	Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HITâ€˜91. European Journal of Cancer, 2009, 45, 1209-1217.	2.8	173
13	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
14	Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-Oncology, 2011, 13, 669-679.	1.2	149
15	Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro-Oncology, 2009, 11, 201-210.	1.2	125
16	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathologica, 2014, 128, 137-149.	7.7	125
17	Frequency, Riskâ€Factors and Survival of Children With Atypical Teratoid Rhabdoid Tumors (AT/RT) of the CNS Diagnosed between 1988 and 2004, and Registered to the German HIT Database. Pediatric Blood and Cancer, 2011, 57, 978-985.	1.5	121
18	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. Journal of Clinical Oncology, 2016, 34, 4151-4160.	1.6	121

#	Article	IF	Citations
19	Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. Journal of Neuro-Oncology, 2016, 129, 515-524.	2.9	99
20	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	27.8	94
21	Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91. Clinical Cancer Research, 2007, 13, 2651-2657.	7.0	90
22	Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: A prospective observational multicentre study. European Journal of Cancer, 2013, 49, 893-903.	2.8	84
23	Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of theCDKN2A locus and other genomic aberrations distinct from medulloblastomas. Genes Chromosomes and Cancer, 2007, 46, 839-851.	2.8	76
24	Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathologica, 2016, 132, 635-637.	7.7	73
25	Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro-Oncology, 2013, 15, 224-234.	1.2	69
26	Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. Journal of Neurosurgery: Pediatrics, 2010, 6, 137-144.	1.3	64
27	Large cell/anaplastic medulloblastoma: Outcome according to myc status, histopathological, and clinical risk factors. Pediatric Blood and Cancer, 2010, 54, 369-376.	1.5	63
28	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	1.6	58
29	Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. Acta Neuropathologica, 2014, 127, 931-933.	7.7	53
30	Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91. Journal of Neuro-Oncology, 2007, 81, 217-223.	2.9	51
31	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathologica, 2020, 139, 243-257.	7.7	50
32	Impairment of intellectual functions after surgery and posterior fossa irradiation in children with ependymoma is related to age and neurologic complications. BMC Cancer, 2008, 8, 15.	2.6	47
33	ETMR: a tumor entity in its infancy. Acta Neuropathologica, 2020, 140, 249-266.	7.7	47
34	Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect <scp>Wnt</scp> activated tumours. Neuropathology and Applied Neurobiology, 2015, 41, 135-144.	3.2	46
35	Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. European Journal of Cancer, 2015, 51, 2634-2642.	2.8	44
36	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathologica, 2021, 141, 771-785.	7.7	44

#	Article	IF	Citations
37	Treatment of Children With Central Nervous System Primitive Neuroectodermal Tumors/Pinealoblastomas in the Prospective Multicentric Trial HIT 2000 Using Hyperfractionated Radiation Therapy Followed by Maintenance Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 863-871.	0.8	39
38	Medulloblastoma. Current Treatment Options in Neurology, 2012, 14, 416-426.	1.8	38
39	A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors. Nature Medicine, 2017, 23, 1191-1202.	30.7	38
40	Strategies to improve the quality of survival for childhood brain tumour survivors. European Journal of Paediatric Neurology, 2015, 19, 619-639.	1.6	36
41	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathologica, 2021, 142, 841-857.	7.7	36
42	Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. Neuro-Oncology, 2015, 17, 1157-1165.	1.2	33
43	Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro-Oncology, 2017, 19, now234.	1.2	33
44	Metastatic medulloblastoma in adults: Outcome of patients treated according to the HIT2000 protocol. European Journal of Cancer, 2015, 51, 2434-2443.	2.8	30
45	CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathologica, 2020, 140, 405-407.	7.7	30
46	Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anti-Cancer Drugs, 2009, 20, 794-799.	1.4	27
47	MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma. Clinical Neuroradiology, 2019, 29, 595-604.	1.9	26
48	Primary central nervous system primitive neuroectodermal tumors (CNS-PNETs) of the spinal cord in children: four cases from the German HIT database with a critical review of the literature. Journal of Neuro-Oncology, 2011, 104, 279-286.	2.9	24
49	Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006. Journal of Neuro-Oncology, 2011, 102, 459-469.	2.9	22
50	Recurrence in childhood medulloblastoma. Journal of Neuro-Oncology, 2011, 103, 705-711.	2.9	22
51	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
52	Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastomaâ€"An Experience From the HIT-REZ 1997 & 2005 Studies. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1019-1024.	0.8	21
53	Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features â€“ a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathologica Communications, 2019, 7, 181.	5.2	21
54	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. Oncologist, 2019, 24, e921-e929.	3.7	19

#	Article	IF	Citations
55	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. Neuro-Oncology, 2021, 23, 1012-1023.	1.2	19
56	A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. European Journal of Cancer, 2012, 48, 2028-2036.	2.8	16
57	Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT trials: clinical findings of a rare disease. Journal of Neurosurgery: Pediatrics, 2015, 15, 227-235.	1.3	16
58	Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. Lancet Oncology, The, 2018, 19, e419-e428.	10.7	16
59	Functional loss of a noncanonical BCORâ€“PRC1.1 complex accelerates SHH-driven medulloblastoma formation. Genes and Development, 2020, 34, 1161-1176.	5.9	16
60	Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups. Journal of Neuro-Oncology, 2013, 111, 337-345.	2.9	14
61	Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment. PLoS ONE, 2020, 15, e0227693.	2.5	14
62	Neuropsychological short assessment of disease- and treatment-related intelligence deficits in children with brain tumours. European Journal of Paediatric Neurology, 2015, 19, 298-307.	1.6	13
63	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma â€“ A Report From the HIT 2000 Trial. Advances in Radiation Oncology, 2020, 5, 1158-1169.	1.2	13
64	A single supratentorial highâ€grade neuroepithelial tumor with two distinct BCOR mutations, exceptionally long complete remission and survival. Pediatric Blood and Cancer, 2020, 67, e28384.	1.5	12
65	Adults with CNS primitive neuroectodermal tumors/pineoblastomas: results of multimodal treatment according to the pediatric HIT 2000 protocol. Journal of Neuro-Oncology, 2014, 116, 567-575.	2.9	10
66	Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial. Neuro-Oncology Practice, 2017, 4, 161-170.	1.6	9
67	Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial. Neuro-Oncology, 2022, 24, 127-137.	1.2	9
68	Ependymoblastoma of the brainstem: MRI findings and differential diagnosis. Pediatric Blood and Cancer, 2014, 61, 1132-1134.	1.5	8
69	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncology Advances, 0, , .	0.7	6
70	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. Neuro-Oncology, 2018, 20, i72-i72.	1.2	4
71	Evidence of neural crest cell origin of a DICER1 mutant CNS sarcoma in a child with DICER1 syndrome and NRASâ€mutant neurocutaneous melanosis. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	4
72	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	2.9	2

#	Article	IF	Citations
73	ETMR-06. Molecular and clinical characteristics of CNS tumors withBCOR(L1) fusion/internal tandem duplication. Neuro-Oncology, 2022, 24, i50-i50.	1.2	2
74	PATH-07. QUALITY ASSURANCE IN CEREBROSPINAL FLUID CYTOLOGY ASSESSMENT FOR MEDULLOBLASTOMA STAGING LEADS TO POTENTIAL IMPROVED RISK-GROUP ASSESSMENT IN THE PROSPECTIVE MULTICENTER HIT-2000 TRIAL. Neuro-Oncology, 2020, 22, iii425-iii426.	1.2	1
75	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	1.2	1
76	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy â€“ Results of the MET-HIT2000-BIS4 trial. Neuro-Oncology, 2022, 24, i104-i104.	1.2	1
77	PNR-09EVALUATION OF AGE-DEPENDENT TREATMENT STRATEGIES FOR CHILDREN AND YOUNG ADULTS WITH PINEOBLASTOMA: ANALYSIS OF POOLED SIOP-E AND HEAD START DATA. Neuro-Oncology, 2016, 18, iii8.3-iii8.	1.2	0
78	MBCL-45. ROLE OF IRRADIATION IN RELAPSED MEDULLOBLASTOMA: A REPORT OF THE GERMAN MEDULLOBLASTOMA RELAPSE STUDIES. Neuro-Oncology, 2018, 20, i127-i127.	1.2	0
79	QOL-10. Treatment-induced leukoencephalopathy in pediatric medulloblastoma survivors and its impact on long-term neurocognitive functioning. Neuro-Oncology, 2022, 24, i135-i135.	1.2	0
80	RONC-16. Proton therapy for patients with embryonal tumor with multilayered rosettes in early childhood â€“ results of the prospective KiProReg Study. Neuro-Oncology, 2022, 24, i180-i180.	1.2	0